"University of Arizona to Conduct Cervical Cancer Vaccine Tests Funded by Merck"

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

 

------------------------------------------------------------

 

April 04, 2003

 

U.S. IMMUNIZATION NEWS

 

"University of Arizona to Conduct Cervical Cancer Vaccine Tests Funded by Merck" Arizona Daily Star (www.azstarnet.com) (04/01/03); Swedlund, Eric

 

A University of Washington phase I study of Merck's cervical cancer vaccine demonstrated that is was 100 percent effective in preventing the disease by stopping human papillomavirus infection.  A larger phase II test will now take place across three continents.  The upcoming trial will also gauge whether the vaccine can prevent pre-cancerous cervical lesions.  A quadrivalent vaccine will be utilized in that study, as opposed to the univalent version used in the phase I test.

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.